Literature DB >> 2047657

Potentially lethal complications of shigellosis.

M L Bennish1.   

Abstract

Complications that can lead to death during shigellosis include intestinal as well as systemic manifestations. The former include intestinal perforation, toxic megacolon, and dehydration, and the latter include sepsis, hyponatremia, hypoglycemia, seizures and encephalopathy, hemolyticuremic syndrome, pneumonia, and malnutrition. Data on the frequency of these complications come primarily from hospital-based studies, in which sepsis-either with Shigella or with other Enterobacteriaceae-and hypoglycemia are the most common causes of death. Management of these two complications requires broad-spectrum empiric antibiotic treatment of all severely ill, malnourished patients with shigellosis as well as frequent feedings to prevent hypoglycemia. Unfortunately, in developing countries, access to parenteral broad-spectrum antimicrobial agents is often limited, and frequent feedings are often precluded by the severe anorexia that is characteristic of shigellosis. Realistic approaches to the reduction of mortality from shigellosis must continue to focus on prevention and early antimicrobial therapy rather than on treatment of established complications.

Entities:  

Mesh:

Year:  1991        PMID: 2047657     DOI: 10.1093/clinids/13.supplement_4.s319

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  29 in total

1.  Enteroaggregative Escherichia coli promotes transepithelial migration of neutrophils through a conserved 12-lipoxygenase pathway.

Authors:  Erik J Boll; Carsten Struve; Anja Sander; Zachary Demma; Karen A Krogfelt; Beth A McCormick
Journal:  Cell Microbiol       Date:  2011-10-27       Impact factor: 3.715

2.  Analysis of epithelial cell stress response during infection by Shigella flexneri.

Authors:  N Mantis; M C Prévost; P Sansonetti
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  Characterization of the Shigella serotype D (S. sonnei) O polysaccharide and the enterobacterial R1 lipopolysaccharide core by use of mouse monoclonal antibodies.

Authors:  J F Viret; U Bruderer; A B Lang
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

4.  Requirement of the Shigella flexneri virulence plasmid in the ability to induce trafficking of neutrophils across polarized monolayers of the intestinal epithelium.

Authors:  B A McCormick; A M Siber; A T Maurelli
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

5.  Bacterial colitis.

Authors:  Harry T Papaconstantinou; J Scott Thomas
Journal:  Clin Colon Rectal Surg       Date:  2007-02

6.  High frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, streptomycin, chloramphenicol, and tetracycline isolated from patients with shigellosis in northeastern Brazil during the period 1988 to 1993.

Authors:  A A Lima; N L Lima; M C Pinho; E A Barros Juñior; M J Teixeira; M C Martins; R L Guerrant
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

7.  Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events.

Authors:  Karen L Mumy; Xinhua Chen; Ciarán P Kelly; Beth A McCormick
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-11-21       Impact factor: 4.052

8.  Peripheral blood neutrophil responses in children with shigellosis.

Authors:  T Azim; L N Islam; R C Halder; J Hamadani; N Khanum; M S Sarker; M A Salam; M J Albert
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

9.  Distinct isoforms of phospholipase A2 mediate the ability of Salmonella enterica serotype typhimurium and Shigella flexneri to induce the transepithelial migration of neutrophils.

Authors:  Karen L Mumy; Jeffrey D Bien; Michael A Pazos; Karsten Gronert; Bryan P Hurley; Beth A McCormick
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

10.  Pneumonia caused by Shigella sonnei in man returned from India.

Authors:  Fabiola Mancini; Antonella Carniato; Alessandra Ciervo
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.